19results about "Platelet-derived growth factor" patented technology

The invention discloses a platelet growth factor derived polypeptide as well as a composition and application thereof. The amino acid sequence of the polypeptide is shown as Seq ID No: 1 (RP1601: LLKLLKKLLKKLLKK). KKIIKKL is used as a core active sequence, a variant library is designed by adopting a special design rule (AABB cycle rule), optimization is carried out by combining a polypeptide activity prediction system with a molecular docking technology, finally five candidate polypeptides are screened out, the polypeptide RP1601 has a better balance expression between drug effect and safety, and the polypeptide RP1601 is simple in structure, easy to synthesize and optimize and high in stability, and can be used for preparing a polypeptide RP1601. Therefore, the polypeptide is determined as an optimal candidate polypeptide; based on excellent anti-inflammatory, repair-promoting and anti-oxidation characteristics of the polypeptide, the invention further provides application of the polypeptide in cosmetics and medicines.

The present invention relates to improved platelet-derived growth factor (PDGF) polypeptide variants, particularly polypeptides comprising the sequence of any one of SEQ ID NOs: 2 to 4 or a sequence having at least 80% similarity thereto, wherein the PDGF polypeptide exhibits increased stability, biological activity and / or solubility compared to the wild-type PDGF polypeptide of SEQ ID NO: 1. The present invention further provides nucleic acid sequences encoding the PDGF polypeptides of the present invention, and also provides a method for growing animal cells, comprising culturing the animal cells in a culture medium containing the PDGF polypeptide of the present invention.

The invention relates to the technical field of biological medicines, in particular to a preparation method of a stem cell factor composition for promoting scalp hair follicle regeneration. The method comprises the following steps: performing high-low oxygen cycle pre-stimulation and stepped hypoxia induction on umbilical cord mesenchymal stem cells, monitoring secretion kinetics of vascular endothelial growth factors (VEGF), hepatocyte growth factors (HGF), keratinocyte growth factors (KGF) and fibroblast growth factors 2 (FGF2) in real time, and determining the optimal collection time; performing ultrafiltration on the supernate to obtain a primary concentrated solution, optimizing the molecular weight cutoff based on the bioactivity retention rate after freezing and thawing, and concentrating to obtain a stem cell factor concentrated solution; the stem cell factor composition is obtained by combining the stem cell factor with a compound nutrition preparation, verifying in-vitro hair follicle cell proliferation / migration activity, dynamically adjusting the nutrition proportion according to the relative efficiency ratio and optimizing. According to the invention, intelligent preparation of the stem cell factor composition with multi-factor synergistic secretion, controllable process, stable activity and adjustable functions is realized.

Methods for generating multipotent radial glia-like cells and astrocyte-like cells from human pluripotent stem cells are provided, along with related compositions.

Provided herein are methods of engineering a cell line for reduced dependence on exogenous growth factor(s). In some embodiments, the method includes introducing into a cell one or more of: a polynucleotide comprising a coding sequence of a growth factor ligand; a polynucleotide comprising a coding sequence of a growth factor receptor; or a polynucleotide comprising a coding sequence of an activated downstream growth factor target, and culturing the cells in a cultivation infrastructure.

This invention relates to a method for producing extracellular matrix using connective tissue cell culture and to the uses of the produced extracellular matrix. More specifically, it relates to a method for culturing connective tissue cells using a serum-free and heterogeneous culture medium, which can be effectively used to increase the amount of extracellular matrix produced. Furthermore, the extracellular matrix produced by the production method of this invention is derived from human cells and does not contain any heterogeneous components such as fetal bovine serum, making it safe and useful for future development of cell therapy agents, medical supplies, medical devices for tissue treatment, or cosmetic raw materials.

The present invention provides a novel blood-derived growth-factor-containing composition. The present invention for solving the above problem is a method for preparing a growth-factor-containing composition from blood, the method comprising a step for separating platelet-rich plasma that does not contain a buffy coat component from the blood, and a step for adding citric acid and / or a salt thereof to the blood or a processed product thereof.

The invention provides a growth factor-dextran conjugate as well as a preparation method and application thereof, the growth factor-dextran conjugate consists of a growth factor and dextran, and is obtained by coupling an amino group of the growth factor and a hydroxyl group of the dextran through a chemical reaction; the growth factor-dextran conjugate can protect the growth factor to enhance the stability of the growth factor, reduce the degradation of the growth factor in vivo and prolong the in vivo half-life period of the growth factor; coupled dextran can be combined with a cell surface receptor to promote cellular uptake of growth factors and enhance the effective action concentration of the growth factors in cells, has good biocompatibility and biological safety, and has wide application in research and development of drugs for wound repair and / or treatment of neurodegenerative diseases.

The present invention relates to a method for producing bone marrow-derived endothelial precursor cells with enhanced angiogenic ability using PDGF-BB, and a method for producing a cell therapeutic agent for treating angiogenesis-related diseases using the same. Specifically, the present invention relates to a method for producing vascular endothelial precursor cells with enhanced angiogenic ability, which comprises the step of treating isolated vascular endothelial precursor cells with PDGF-BB and culturing them, a composition for promoting angiogenesis comprising vascular endothelial precursor cells and PDGF-BB as active ingredients, a method for producing a cell therapeutic agent for treating angiogenesis-related diseases, which comprises the step of mixing isolated vascular endothelial precursor cells, mesenchymal stem cells and PDGF-BB, and the cell therapeutic agent for treating angiogenesis-related diseases produced by the method.

Disclosed herein are compositions, methods, and systems for the purification and / or detection of recombinant and other proteins. In some embodiments, compositions may comprise recombinant protein with one or more sequences having substantial homology to RP-Tag Small or RP-Tag Large. In some cases, the disclosed compositions may be useful in binding or recognizing target proteins.

The present invention relates to peptide ligands that bind to an extracellular or transmembrane region of PDGFR-alpha. The invention also relates to compositions comprising the peptide ligands and methods of using the same.

Provided herein are methods of engineering a cell line for reduced dependence on exogenous growth factor(s). In some embodiments, the method includes introducing into a cell one or more of: a polynucleotide comprising a coding sequence of a growth factor ligand; a polynucleotide comprising a coding sequence of a growth factor receptor; or a polynucleotide comprising a coding sequence of an activated downstream growth factor target, and culturing the cells in a cultivation infrastructure.

The targeted delivery of growth factors, vasoactive peptides and other representative anabolic peptide drugs from different signaling cascades to bone fracture for accelerated healing is disclosed herein.

The present application is directed to PDGF-D prodomain or its mutant or fusion. The present application is also directed to a process or use of the PDGF-D prodomain or its mutant or fusion for inhibiting PDGFR phosphorylation, for inhibiting cell proliferation stimulated by PDGF, or for preventing and / or treating diseases associated therewith.

Provided herein is bioactive protein / peptide-modified PPCN (e.g., A5G81, QK, VEGF-C, etc.) and methods of ocular delivery and treatment of disease (e.g., glaucoma) therewith.

Disclosed herein are compounds of formula (I) wherein X, L1, and HSA conjugate are as defined herein, methods of preparation thereof, and methods of using thereof for improving cardiac repair, particularly post infarct.

A composition of rhPDGF-BB for the regeneration, rejuvenation, strengthening, comfort or aesthetic usefulness of soft tissue in the field of cosmetics and cosmeceuticals, comprising rhPDGF-BB combined with a carrier selected from the group consisting of different types of collagen, gelatin, alginates, polysaccharides, glycosaminoglycans, fibrin, hyaluronic acid and derivatives or combinations thereof, wherein damage to skin or soft tissue is treated by application of the disclosed composition.

A nonviral gene therapy delivers DNA that allows cells to produce proteins such as their own growth factors in culture media. Lipid nanoparticles provide an effective delivery mechanism into a target cell. By encapsulating plasmid DNA encoding the growth factors with inducible promoters into lipid nanoparticles (LNPs), target cells create their own growth factors reducing a need for expensive growth factors from external sources. DNA expression lasts for several days reducing the amount of reagent needed. The plasmid DNA is more stable than mRNA and proteins, therefore reducing logistical challenges.